Stimulant prodrugs: A pharmacological and clinical assessment of their role in treating ADHD and binge-eating disorder
Adv Pharmacol. 2024;99:251-286. doi: 10.1016/bs.apha.2023.10.002. Epub 2023 Oct 25.ABSTRACTIn this review, we critically evaluate the contribution of prodrugs to treating two related psychiatric disorders, attention-deficit hyperactivity disorder (ADHD) and binge-eating disorder (BED). ADHD is characterized by inattentiveness, distractibility, impulsiveness, and hyperactivity. BED is also an impulse-control disorder which leads to frequent, compulsive episodes of excessive eating (binges). Lisdexamfetamine (LDX; prodrug of d-amphetamine) is approved to treat both ADHD and BED. Serdexmethylphenidate (SDX; prodrug of d-threo...
Source: Advances in Pharmacology - March 11, 2024 Category: Drugs & Pharmacology Authors: David J Heal Jane Gosden Sharon L Smith Source Type: research

Stimulant prodrugs: A pharmacological and clinical assessment of their role in treating ADHD and binge-eating disorder
Adv Pharmacol. 2024;99:251-286. doi: 10.1016/bs.apha.2023.10.002. Epub 2023 Oct 25.ABSTRACTIn this review, we critically evaluate the contribution of prodrugs to treating two related psychiatric disorders, attention-deficit hyperactivity disorder (ADHD) and binge-eating disorder (BED). ADHD is characterized by inattentiveness, distractibility, impulsiveness, and hyperactivity. BED is also an impulse-control disorder which leads to frequent, compulsive episodes of excessive eating (binges). Lisdexamfetamine (LDX; prodrug of d-amphetamine) is approved to treat both ADHD and BED. Serdexmethylphenidate (SDX; prodrug of d-threo...
Source: Advances in Pharmacology - March 11, 2024 Category: Drugs & Pharmacology Authors: David J Heal Jane Gosden Sharon L Smith Source Type: research

Stimulant prodrugs: A pharmacological and clinical assessment of their role in treating ADHD and binge-eating disorder
Adv Pharmacol. 2024;99:251-286. doi: 10.1016/bs.apha.2023.10.002. Epub 2023 Oct 25.ABSTRACTIn this review, we critically evaluate the contribution of prodrugs to treating two related psychiatric disorders, attention-deficit hyperactivity disorder (ADHD) and binge-eating disorder (BED). ADHD is characterized by inattentiveness, distractibility, impulsiveness, and hyperactivity. BED is also an impulse-control disorder which leads to frequent, compulsive episodes of excessive eating (binges). Lisdexamfetamine (LDX; prodrug of d-amphetamine) is approved to treat both ADHD and BED. Serdexmethylphenidate (SDX; prodrug of d-threo...
Source: Advances in Pharmacology - March 11, 2024 Category: Drugs & Pharmacology Authors: David J Heal Jane Gosden Sharon L Smith Source Type: research

Stimulant prodrugs: A pharmacological and clinical assessment of their role in treating ADHD and binge-eating disorder
Adv Pharmacol. 2024;99:251-286. doi: 10.1016/bs.apha.2023.10.002. Epub 2023 Oct 25.ABSTRACTIn this review, we critically evaluate the contribution of prodrugs to treating two related psychiatric disorders, attention-deficit hyperactivity disorder (ADHD) and binge-eating disorder (BED). ADHD is characterized by inattentiveness, distractibility, impulsiveness, and hyperactivity. BED is also an impulse-control disorder which leads to frequent, compulsive episodes of excessive eating (binges). Lisdexamfetamine (LDX; prodrug of d-amphetamine) is approved to treat both ADHD and BED. Serdexmethylphenidate (SDX; prodrug of d-threo...
Source: Advances in Pharmacology - March 11, 2024 Category: Drugs & Pharmacology Authors: David J Heal Jane Gosden Sharon L Smith Source Type: research

Stimulant prodrugs: A pharmacological and clinical assessment of their role in treating ADHD and binge-eating disorder
Adv Pharmacol. 2024;99:251-286. doi: 10.1016/bs.apha.2023.10.002. Epub 2023 Oct 25.ABSTRACTIn this review, we critically evaluate the contribution of prodrugs to treating two related psychiatric disorders, attention-deficit hyperactivity disorder (ADHD) and binge-eating disorder (BED). ADHD is characterized by inattentiveness, distractibility, impulsiveness, and hyperactivity. BED is also an impulse-control disorder which leads to frequent, compulsive episodes of excessive eating (binges). Lisdexamfetamine (LDX; prodrug of d-amphetamine) is approved to treat both ADHD and BED. Serdexmethylphenidate (SDX; prodrug of d-threo...
Source: Advances in Pharmacology - March 11, 2024 Category: Drugs & Pharmacology Authors: David J Heal Jane Gosden Sharon L Smith Source Type: research

Stimulant prodrugs: A pharmacological and clinical assessment of their role in treating ADHD and binge-eating disorder
Adv Pharmacol. 2024;99:251-286. doi: 10.1016/bs.apha.2023.10.002. Epub 2023 Oct 25.ABSTRACTIn this review, we critically evaluate the contribution of prodrugs to treating two related psychiatric disorders, attention-deficit hyperactivity disorder (ADHD) and binge-eating disorder (BED). ADHD is characterized by inattentiveness, distractibility, impulsiveness, and hyperactivity. BED is also an impulse-control disorder which leads to frequent, compulsive episodes of excessive eating (binges). Lisdexamfetamine (LDX; prodrug of d-amphetamine) is approved to treat both ADHD and BED. Serdexmethylphenidate (SDX; prodrug of d-threo...
Source: Advances in Pharmacology - March 11, 2024 Category: Drugs & Pharmacology Authors: David J Heal Jane Gosden Sharon L Smith Source Type: research

Stimulant prodrugs: A pharmacological and clinical assessment of their role in treating ADHD and binge-eating disorder
Adv Pharmacol. 2024;99:251-286. doi: 10.1016/bs.apha.2023.10.002. Epub 2023 Oct 25.ABSTRACTIn this review, we critically evaluate the contribution of prodrugs to treating two related psychiatric disorders, attention-deficit hyperactivity disorder (ADHD) and binge-eating disorder (BED). ADHD is characterized by inattentiveness, distractibility, impulsiveness, and hyperactivity. BED is also an impulse-control disorder which leads to frequent, compulsive episodes of excessive eating (binges). Lisdexamfetamine (LDX; prodrug of d-amphetamine) is approved to treat both ADHD and BED. Serdexmethylphenidate (SDX; prodrug of d-threo...
Source: Advances in Pharmacology - March 11, 2024 Category: Drugs & Pharmacology Authors: David J Heal Jane Gosden Sharon L Smith Source Type: research

Stimulant prodrugs: A pharmacological and clinical assessment of their role in treating ADHD and binge-eating disorder
Adv Pharmacol. 2024;99:251-286. doi: 10.1016/bs.apha.2023.10.002. Epub 2023 Oct 25.ABSTRACTIn this review, we critically evaluate the contribution of prodrugs to treating two related psychiatric disorders, attention-deficit hyperactivity disorder (ADHD) and binge-eating disorder (BED). ADHD is characterized by inattentiveness, distractibility, impulsiveness, and hyperactivity. BED is also an impulse-control disorder which leads to frequent, compulsive episodes of excessive eating (binges). Lisdexamfetamine (LDX; prodrug of d-amphetamine) is approved to treat both ADHD and BED. Serdexmethylphenidate (SDX; prodrug of d-threo...
Source: Advances in Pharmacology - March 11, 2024 Category: Drugs & Pharmacology Authors: David J Heal Jane Gosden Sharon L Smith Source Type: research

Long-term low-dose lamotrigine for paroxysmal kinesigenic dyskinesia: a two-year investigation of cognitive function in children
ConclusionProlonged duration of untreated PKD in children may elevate the risk of ADHD comorbidity. Notably, following a 2-year lamotrigine regimen, enhancements were observed in both cognitive test outcomes and ADHD symptomatology. (Source: Frontiers in Psychiatry)
Source: Frontiers in Psychiatry - March 11, 2024 Category: Psychiatry Source Type: research

Sleep Physiology and Neurocognition Among Adolescents With Attention-Deficit/Hyperactivity Disorder
This study investigates differences in PSG-measured sleep among adolescents with ADHD versus non-psychiatric controls (NPC) and associations with neurocognition. (Source: Journal of the American Academy of Child and Adolescent Psychiatry)
Source: Journal of the American Academy of Child and Adolescent Psychiatry - March 11, 2024 Category: Psychiatry Authors: Jessica R. Lunsford-Avery, Mary A. Carskadon, Scott H. Kollins, Andrew D. Krystal Tags: New Research Source Type: research

Effect of biofeedback intervention on neurological characteristics of children with attention deficit hyperactivity disorder
. (Source: International Journal of Neuroscience)
Source: International Journal of Neuroscience - March 11, 2024 Category: Neuroscience Authors: Cai ZhangXiaoxuan ZhouNanfei HuLin XuDepartment of Pediatrics, Brain Hospital of Hunan Province (The Second People ’s Hospital of Hunan Province) College of Clinical Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, P.R. China Source Type: research

Neurologic changes induced by whole-brain synchrotron microbeam irradiation: 10 months behavioral and veterinary follow-up
CONCLUSIONS: While acute toxicity of microbeam exposures depends on very high peak doses, late toxicity mainly relates to delivery of high MBI valley doses. MBI seems to elicit low impact on normal rat behavior but further tests are warranted to fully explore this hypothesis. However, high peak and valley doses are well tolerated from a veterinary point of view. This normal tissue tolerance to whole-brain, high-dose MBI reveals a promising avenue for MRT, i.e., therapeutic applications of microbeams which are poised for translation to a clinical environment.PMID:38462014 | DOI:10.1016/j.ijrobp.2024.02.053 (Source: Health Physics)
Source: Health Physics - March 10, 2024 Category: Physics Authors: L Eling C Verry J Balosso I Flandin S Kefs A Bouchet J F Adam J A Laissue R Serduc Source Type: research

Novel pharmacological targets for GABAergic dysfunction in ADHD
Neuropharmacology. 2024 Mar 8:109897. doi: 10.1016/j.neuropharm.2024.109897. Online ahead of print.ABSTRACTAttention deficit/hyperactivity disorder (ADHD) is a neurodevelopment disorder that affects approximately 5% of the population. The disorder is characterized by impulsivity, hyperactivity, and deficits in attention and cognition, although symptoms vary across patients due to the heterogenous and polygenic nature of the disorder. Stimulant medications are the standard of care treatment for ADHD patients, and their effectiveness has led to the dopaminergic hypothesis of ADHD in which deficits in dopaminergic signaling, ...
Source: Neuropharmacology - March 10, 2024 Category: Drugs & Pharmacology Authors: Anthony S Ferranti Deborah J Luessen Colleen M Niswender Source Type: research

Arousal, Gray's Theory of Anxiety, and the Etiology of Psychopathy
Biol Psychol. 2024 Mar 8:108772. doi: 10.1016/j.biopsycho.2024.108772. Online ahead of print.ABSTRACTThis paper focuses on Jeffrey Gray's theory of anxiety from the perspective of Fowles' (1980) application of his work to theories of arousal, psychophysiology, and the etiology of psychopathy. Although highly influential, the concept of general arousal failed to find support in terms of between-individuals assessment with multiple physiological measures. Gray's constructs of a behavioral inhibition system (BIS) that mediates anxiety, a behavioral approach or activation system (BAS) that energizes behavior to approach reward...
Source: Biological Psychology - March 10, 2024 Category: Psychiatry & Psychology Authors: Don C Fowles Source Type: research

Novel pharmacological targets for GABAergic dysfunction in ADHD
Neuropharmacology. 2024 Mar 8:109897. doi: 10.1016/j.neuropharm.2024.109897. Online ahead of print.ABSTRACTAttention deficit/hyperactivity disorder (ADHD) is a neurodevelopment disorder that affects approximately 5% of the population. The disorder is characterized by impulsivity, hyperactivity, and deficits in attention and cognition, although symptoms vary across patients due to the heterogenous and polygenic nature of the disorder. Stimulant medications are the standard of care treatment for ADHD patients, and their effectiveness has led to the dopaminergic hypothesis of ADHD in which deficits in dopaminergic signaling, ...
Source: Neuropharmacology - March 10, 2024 Category: Drugs & Pharmacology Authors: Anthony S Ferranti Deborah J Luessen Colleen M Niswender Source Type: research